Cargando…
A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry
SARS-CoV-2 (2019-nCoV) is the pathogenic coronavirus responsible for the global pandemic of COVID-19 disease. The Spike (S) protein of SARS-CoV-2 attaches to host lung epithelial cells through the cell surface receptor ACE2, a process dependent on host proteases including TMPRSS2. Here, we identifie...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430593/ https://www.ncbi.nlm.nih.gov/pubmed/32818215 http://dx.doi.org/10.21203/rs.3.rs-48659/v1 |
_version_ | 1783571450073972736 |
---|---|
author | Chen, Yanwen Lear, Travis B. Evankovich, John W. Larsen, Mads B. Lin, Bo Alfaras, Irene Kennerdell, Jason R. Salminen, Laura Camarco, Daniel P. Lockwood, Karina C. Liu, Jie Myerburg, Michael M. McDyer, John F. Liu, Yuan Finkel, Toren Chen, Bill B. |
author_facet | Chen, Yanwen Lear, Travis B. Evankovich, John W. Larsen, Mads B. Lin, Bo Alfaras, Irene Kennerdell, Jason R. Salminen, Laura Camarco, Daniel P. Lockwood, Karina C. Liu, Jie Myerburg, Michael M. McDyer, John F. Liu, Yuan Finkel, Toren Chen, Bill B. |
author_sort | Chen, Yanwen |
collection | PubMed |
description | SARS-CoV-2 (2019-nCoV) is the pathogenic coronavirus responsible for the global pandemic of COVID-19 disease. The Spike (S) protein of SARS-CoV-2 attaches to host lung epithelial cells through the cell surface receptor ACE2, a process dependent on host proteases including TMPRSS2. Here, we identified small molecules that can reduce surface expression of TMPRSS2 using a 2,700 FDA-approved or current clinical trial compounds. Among these, homoharringtonine and halofuginone appear the most potent agents, reducing endogenous TMPRSS2 expression at sub-micromolar concentrations. These effects appear to be mediated by a drug-induced alteration in TMPRSS2 protein stability. We further demonstrate that halofuginone modulates TMPRSS2 levels through proteasomal-mediated degradation that involves the E3 ubiquitin ligase component DDB1- and CUL4-associated factor 1 (DCAF1). Finally, cells exposed to homoharringtonine and halofuginone, at concentrations of drug known to be achievable in human plasma, demonstrated marked resistance to SARS-CoV-2 pseudoviral infection. Given the safety and pharmacokinetic data already available for the compounds identified in our screen, these results should help expedite the rational design of human clinical trials designed to combat COVID-19 infection. |
format | Online Article Text |
id | pubmed-7430593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Journal Experts |
record_format | MEDLINE/PubMed |
spelling | pubmed-74305932020-08-18 A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry Chen, Yanwen Lear, Travis B. Evankovich, John W. Larsen, Mads B. Lin, Bo Alfaras, Irene Kennerdell, Jason R. Salminen, Laura Camarco, Daniel P. Lockwood, Karina C. Liu, Jie Myerburg, Michael M. McDyer, John F. Liu, Yuan Finkel, Toren Chen, Bill B. Res Sq Article SARS-CoV-2 (2019-nCoV) is the pathogenic coronavirus responsible for the global pandemic of COVID-19 disease. The Spike (S) protein of SARS-CoV-2 attaches to host lung epithelial cells through the cell surface receptor ACE2, a process dependent on host proteases including TMPRSS2. Here, we identified small molecules that can reduce surface expression of TMPRSS2 using a 2,700 FDA-approved or current clinical trial compounds. Among these, homoharringtonine and halofuginone appear the most potent agents, reducing endogenous TMPRSS2 expression at sub-micromolar concentrations. These effects appear to be mediated by a drug-induced alteration in TMPRSS2 protein stability. We further demonstrate that halofuginone modulates TMPRSS2 levels through proteasomal-mediated degradation that involves the E3 ubiquitin ligase component DDB1- and CUL4-associated factor 1 (DCAF1). Finally, cells exposed to homoharringtonine and halofuginone, at concentrations of drug known to be achievable in human plasma, demonstrated marked resistance to SARS-CoV-2 pseudoviral infection. Given the safety and pharmacokinetic data already available for the compounds identified in our screen, these results should help expedite the rational design of human clinical trials designed to combat COVID-19 infection. American Journal Experts 2020-08-14 /pmc/articles/PMC7430593/ /pubmed/32818215 http://dx.doi.org/10.21203/rs.3.rs-48659/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Chen, Yanwen Lear, Travis B. Evankovich, John W. Larsen, Mads B. Lin, Bo Alfaras, Irene Kennerdell, Jason R. Salminen, Laura Camarco, Daniel P. Lockwood, Karina C. Liu, Jie Myerburg, Michael M. McDyer, John F. Liu, Yuan Finkel, Toren Chen, Bill B. A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry |
title | A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry |
title_full | A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry |
title_fullStr | A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry |
title_full_unstemmed | A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry |
title_short | A high throughput screen for TMPRSS2 expression identifies FDA-approved and clinically advanced compounds that can limit SARS-CoV-2 entry |
title_sort | high throughput screen for tmprss2 expression identifies fda-approved and clinically advanced compounds that can limit sars-cov-2 entry |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430593/ https://www.ncbi.nlm.nih.gov/pubmed/32818215 http://dx.doi.org/10.21203/rs.3.rs-48659/v1 |
work_keys_str_mv | AT chenyanwen ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT leartravisb ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT evankovichjohnw ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT larsenmadsb ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT linbo ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT alfarasirene ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT kennerdelljasonr ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT salminenlaura ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT camarcodanielp ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT lockwoodkarinac ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT liujie ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT myerburgmichaelm ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT mcdyerjohnf ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT liuyuan ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT finkeltoren ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT chenbillb ahighthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT chenyanwen highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT leartravisb highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT evankovichjohnw highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT larsenmadsb highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT linbo highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT alfarasirene highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT kennerdelljasonr highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT salminenlaura highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT camarcodanielp highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT lockwoodkarinac highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT liujie highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT myerburgmichaelm highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT mcdyerjohnf highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT liuyuan highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT finkeltoren highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry AT chenbillb highthroughputscreenfortmprss2expressionidentifiesfdaapprovedandclinicallyadvancedcompoundsthatcanlimitsarscov2entry |